Brief: Cryoport Q2 Revenue USD 45.5 Million Vs. IBES Estimate USD 41.7 Million

CryoPort

05/08/2025 21:20

Overview

Cryoport Q2 2025 revenue grows 14% yr/yr, beating analyst expectations

Life Sciences Services revenue rises 21%, driven by cell & gene therapy demand

Outlook

Cryoport reaffirms 2025 revenue guidance of $165 mln to $172 mln

Company expects 20 more application filings in 2025

Cryoport anticipates one new therapy approval in 2025

Result Drivers

CELL & GENE THERAPY DEMAND - Revenue from commercial cell & gene therapies increased 33% yr/yr, driven by growing adoption

BIOLOGISTICS SOLUTIONS - Revenue from BioLogistics Solutions rose 20% yr/yr, reflecting strong demand for integrated platform

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$45.50 mln
$41.70 mln (9 Analysts)
Q2 Gross Margin
47.0%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the courier, postal, air freight & land-based logistics peer group is "buy"

Wall Street's median 12-month price target for Cryoport Inc is $10.50, about 31.8% above its August 4 closing price of $7.16

Press Release: ID:nPn9QvxxVa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)